Choriogonadotropin Alpha
- Atc Codes:G03GA08
- CAS Codes:177073-44-8#56832-30-5#56832-34-9
- PHARMGKB ID:177073-44-8#56832-30-5#56832-34-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ovitrelle; Belgium: Ovitrelle; Bulgaria: Ovitrelle; Cyprus: Ovitrelle; Czech Republic: Ovitrelle; Denmark: Ovitrelle; Estonia: Ovitrelle; Finland: Ovitrelle; France: Ovitrelle; Germany: Ovitrelle; Greece: Ovitrelle; Hungary: Ovitrelle; Ireland: Ovitrelle; Italy: Ovitrelle; Latvia: Ovitrelle; Lithuania: Ovitrelle; Luxembourg: Ovitrelle; Malta: Ovitrelle; Netherlands: Ovitrelle; Poland: Ovitrelle; Portugal: Ovitrelle; Romania: Ovitrelle; Slovakia: Ovitrelle; Slovenia: Ovitrelle; Spain: Ovitrelle; Sweden: Ovitrelle; UK: Ovitrelle.
North America
Canada: Ovidrel; USA: Ovidrel.
Latin America
Argentina: Ovidrel; Brazil: Ovidrel; Mexico: Ovidrel.
Drug combinations
Chemistry
Choriogonadotropin Alpha: C~437~H~682~N~122~O~134~S~13~ (α-subunit); C~668~H~1090~N~196~O~203~S~13~ (β-subunit). Mw: 38000.01. (1) Gonadotropin, chorionic (human α-subunit protein moiety reduced), complex with chorionic gonadotropin (human β-subunit protein moiety reduced); (2) Human chorionic gonadotropin (α-subunit protein moiety reduced), complex with human chorionic gonadotropin (β-subunit protein moiety reduced). CAS-177073-44-8; CAS-56832-30-5 (α-subunit); CAS-56832-34-9 (β-subunit)(2000).
Pharmacologic Category
Gonadotropins. Ovulation Stimulator. (ATC-Code: G03GA08).
Mechanism of action
Luteinizing hormone analog produced by recombinant DNA techniques. Stimulates late follicular maturation and intitates rupture of the ovarian follicle once follicular development has occurred.
Therapeutic use
To induce ovulation in infertile females who have been pre-treated with follicle-stimulating hormones. To induce ovulation and pregnancy in infertile females when the cause of infertility is functional.
Pregnancy and lactiation implications
Intrauterine death and impaired birth observed in animal studies. Ectopic pregnancy, premature labor, postpartum fever, and spontaneous abortion reported. Congenital abnormalities also observed, although the incidence is similar during natural conception. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to human chorionic gonadotropin preparations or any component of the formulation. Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Uncontrolled organic intracranial lesion (i.e. pituitary tumor). Abnormal uterine bleeding, ovarian cyst or enlargement of undetermined origin. Sex hormone dependent tumors. Pregnancy.
Warnings and precautions
May be accompanied by abdominal distention or abdominal pain. May cause ovarian hyperstimulation syndrome. Arterial thromboembolic events reported. Risk of multiple births. May interfere with interpretation of pregnancy tests. May cross-react with radioimmunoassay of luteinizing hormone and other gonadotropins.